|
Market Closed -
Nasdaq
21:00:00 15/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 4.350 USD | +4.82% |
|
+3.57% | -29.27% |
Company Valuation: Myriad Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,204 | 1,176 | 1,697 | 1,248 | 573.3 | 416.1 | - | - |
| Change | - | -46.65% | 44.34% | -26.46% | -54.07% | -27.42% | - | - |
| Enterprise Value (EV) 1 | 1,864 | 1,061 | 1,595 | 1,185 | 543.6 | 367.1 | 348.3 | 315.4 |
| Change | - | -43.09% | 50.32% | -25.67% | -54.14% | -32.47% | -5.11% | -9.45% |
| P/E | -78.9x | -10.4x | -6.02x | -9.72x | -1.56x | -2.78x | -3.33x | -3.61x |
| PBR | 2.28x | 1.33x | 2.2x | 1.79x | 1.56x | 1.22x | 1.29x | 1.25x |
| PEG | - | -0x | -0x | 0.2x | -0x | 0x | 0.2x | 0.46x |
| Capitalization / Revenue | 3.19x | 1.73x | 2.25x | 1.49x | 0.7x | 0.53x | 0.51x | 0.48x |
| EV / Revenue | 2.7x | 1.56x | 2.12x | 1.42x | 0.66x | 0.47x | 0.42x | 0.36x |
| EV / EBITDA | 25.9x | -50.5x | -253x | 29.3x | 14x | -6.68x | -9.75x | -18.8x |
| EV / EBIT | 205x | -32.3x | -62.5x | 54.4x | 36x | -4.94x | -5.97x | -10.4x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.35 | -1.39 | -3.18 | -1.41 | -3.95 | -1.567 | -1.307 | -1.205 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 690.6 | 678.4 | 753.2 | 837.6 | 824.5 | 777.9 | 820.5 | 870.9 |
| EBITDA 1 | 71.9 | -21 | -6.3 | 40.4 | 38.9 | -54.98 | -35.73 | -16.75 |
| EBIT 1 | 9.1 | -32.8 | -25.5 | 21.8 | 15.1 | -74.3 | -58.34 | -30.26 |
| Net income 1 | -27.2 | -112 | -263.3 | -127.3 | -365.9 | -139.6 | -106.2 | -117.5 |
| Net Debt 1 | -339.8 | -114.9 | -102.4 | -62.8 | -29.7 | -48.99 | -67.76 | -100.7 |
| Reference price 2 | 27.600 | 14.510 | 19.140 | 13.710 | 6.150 | 4.350 | 4.350 | 4.350 |
| Nbr of stocks (in thousands) | 79,855 | 81,034 | 88,669 | 91,035 | 93,214 | 95,650 | - | - |
| Announcement Date | 24/02/22 | 28/02/23 | 27/02/24 | 24/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.65x | 0.45x | -6.33x | -.--% | 397M | |
| 30.38x | 4.03x | 15.56x | 2.5% | 178B | |
| 20.17x | 3.63x | 13.01x | 2.99% | 121B | |
| 21.93x | 4.3x | 15.02x | 1.28% | 108B | |
| 26.23x | 2.58x | 10.35x | 2.73% | 75.7B | |
| 18.44x | 0.21x | 13.38x | 0.71% | 64.15B | |
| 30.93x | 7.69x | 19.79x | 1.29% | 53.49B | |
| 36.4x | 3.49x | 11.96x | 2.08% | 51.45B | |
| 35.83x | 8.9x | 24.94x | -.--% | 41.68B | |
| 48.27x | 1.33x | 12.29x | 0.2% | 31.52B | |
| Average | 26.59x | 3.66x | 13.00x | 1.38% | 72.51B | |
| Weighted average by Cap. | 27.47x | 3.91x | 14.76x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MYGN Stock
- Valuation Myriad Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
